UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
InMed Pharmaceuticals Inc. |
||
(Address of Principal Executive Offices) | (Zip Code) |
Company’s
telephone number, including area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On September 9, 2021, the Company announced that Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which is being held virtually from September 13-15, 2021.
The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No. |
Description | |
99.1 |
News release, dated September 9, 2021 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INMED PHARMACEUTICALS INC. | ||
Date: September 9, 2021 | By: | /s/ Bruce Colwill |
Bruce Colwill | ||
Chief Financial Officer |
2
Exhibit 99.1
|
NASDAQ: INM
Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com |
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, BC – September 9, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which is being held virtually from September 13-15, 2021.
The on-demand presentation will be available at 1:00 pm ET on September 13, 2021 and can be accessed from the H.C. Wainwright events platform at HCW Events. An archived replay of the presentation will be available on the Company’s website immediately following the conference and will be available for 90 days.
InMed’s management team will also be conducting meetings with institutional investors throughout the conference. To schedule a meeting, please contact your H.C. Wainwright representative or register for the event at HCW Events.
Information on this event will also be posted on InMed’s event page, which can be found at: www.inmedpharma.com/about/events.
About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com
Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: presenting at H.C. Wainwright 23rd Annual Global Investment Conference; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; advancing IntegraSyn™ to commercial scale production; IntegraSyn™ being a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
O M&=W6LK7_ =_;>IR:@E^;>=8K=8/W(<1R0RM*K$$_,"6P5X^OH[BL\:T:$*)IA$RO&2,E?O CKGVK9NY_$MOKVEZ NN6QDNX M;BX>[-@-P6,Q@*%W8_C//Z4ZX\&ZCJLEY<:KK$+SW$=M"/LUH8U1(9_-Z%SD ML21["MZYT47/B;3]9^T%39V\T AVY#>84. \1ZEJ']EZA M;:;8V$PMP9+;SWFDV*[9^8!5&\ 8Y.":YNY^(=XT-]JMMJMDB6LTB0Z0ULS2 M7*1L5;,@^Z[88J "!QG/..J/AK5=/U"YGT+68K:.\VO<075MYR^8JA#(F&4@ MD*N1R,C/>BT\-ZQI$TL.D:U;Q:;+<&?[/<6?F-$6;?(J,''RL2Q (.,]Z- U M':?KUY=Z9XDNF"!K"YFCMP4QA5B1UW#URQK!\,R:MJ_BB\U"&_AM3+IVFS72 M&V\SS"R.Q"G<-G<=#UK9O/"VIK=ZJ=(UB&UL]5)>X@GM/-V2% C.A#+C( X. M1D9[TEKX2U'2+N"71]8BA0V5O9W*3VOF>8(00KJ0PVG!((Y'2C0#)TC6]4U, MVNC:0++39G-W ((+Z\O[;7;,7.H1HEX)+ LF5!"M'B0%<*<8)()&>,FC0-3 M$MM>U"637/$&F6*S7TVAZ; !RVT$G Y...O/5>$[]]1LY+C_A( M;?68R0 T-L(3$?XE9 U7=$\/W5EK5]K.HWL-Q>W<4<+"VM_)C"H6()!+%F^8\D],#M0V@1T M%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " :BBB@ HHHH **** "BBB@ HHHH **** /_]D! end
Cover |
Sep. 09, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 09, 2021 |
Entity File Number | 001-39685 |
Entity Registrant Name | INMED PHARMACEUTICALS INC. |
Entity Central Index Key | 0001728328 |
Entity Tax Identification Number | 98-1428279 |
Entity Incorporation, State or Country Code | A1 |
Entity Address, Address Line One | Suite 310 - 815 W. Hastings Street, |
Entity Address, City or Town | Vancouver, B.C. |
Entity Address, Country | CA |
Entity Address, Postal Zip Code | V6C 1B4 |
City Area Code | 604 |
Local Phone Number | 669-7207 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Shares, no par value |
Trading Symbol | INM |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
M-8?20$3;8T.P6BP^0"X99K>]9!:G
8Y#$3L8B0T(Z@E6'(7 &$1I:,0,KRC=9(O-(:&?X)
M^\)+\)#P(B81/O)AS*0JZNYK'Y*P_G/R7^?0K262O=HANI*:G&<%K"#T?J4,
M\/+3#3,#2QS %LE-OE79F_8A$B]ORJ(\@V!?#UZT+$AS:8NIJQ,YX*"7N//7
M9:G_IB,4:N6SRWS]IBI>MKCYA[V_'3H3KP_R"@1^NY3YF8=E4W8AE06&:PZ0
MCETN$]*4^R^0\>-*#LL,-T [B=BS02#X;*+&P'L47^;#_!9MPHAK02J(3JMPTA1%=FEO;T'/XH@A0
M'!H?U#<*@3%4A.FJ<^#KWFYP+ZDMOG&_W(M8[9;_ 5!+ 0(4 Q0 ( *8Q
M*E-